Vistagen Presents Exploratory Data on PH80's Effects on Menopausal Hot Flashes

Vistagen presented exploratory data at The Menopause Society 2025 Annual Meeting demonstrating PH80's potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms due to menopause. PH80 reduced autonomic nervous system activity after intranasal administration and was not absorbed into the bloodstream in humans. The research showed PH80's rapidly-acting, neurocircuitry-focused effects without binding to steroid hormone receptors or neurotransmitter receptors associated with abuse.